• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Moderna's Rally Is Not Over: Our Latest Trading Strategy

Thursday's rally was sparked by news that Moderna's Covid-19 vaccine candidate is moving to Phase II testing.
By BRUCE KAMICH
May 08, 2020 | 11:30 AM EDT
Stocks quotes in this article: MRNA

Jim Cramer commented in a Real Money column that Thursday's rally was sparked by news that Moderna's (MRNA) Covid-19 vaccine candidate is moving to Phase II testing. If a vaccine is indeed just around the corner, that sheds new light on the 3.17 million people who filed for unemployment this week.

But that's a big if, Cramer cautioned. Most vaccines take years to refine and make effective. Moderna would need to see everything go perfectly. We last looked at MRNA stock back on April 17 where we said, "MRNA is likely to gap higher today. Longs should raise sell stop protection to at least $32. $53 and $71 are our potential price targets now."

With MRNA passing our $53 price target let's roll up our sleeves and check out the latest charts of MRNA.  

In the daily bar chart of MRNA, below, we can see that prices have been consolidating in a $45-$55 trading range. Prices are above the rising 50-day simple moving average line and above the rising 200-day simple moving average line.

The daily trading volume has been active since late February and tells us that traders and investors have been attracted to the stock. The daily On-Balance-Volume (OBV) line shows an uptrend from September and confirms the price gains. Buyers of MRNA have been more aggressive these past months.

The Moving Average Convergence Divergence (MACD) oscillator has been above the zero line for much of the past 12 months and has turned upward to a fresh buy signal. 

 
In this weekly bar chart of MRNA, below, we can see that all the indicators are in a bullish alignment. 
 
 
 
In this daily Point and Figure chart of MRNA, below, we used a traditional even dollar increment to create the chart. A trade at $57 will refresh the uptrend and a price target of $73 is now being projected.  
 
 
 
Bottom-line strategy: Longs can raise sell stops to $45 and our new price target is the $73 area.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Healthcare | Life Sciences | Pharmaceuticals | Mad Money | Coronavirus

More from Stocks

Traders: Keep Your Fingers on the Trigger and Targets on a Bottom

James "Rev Shark" DePorre
Mar 4, 2021 4:39 PM EST

As the correction goes on, here's what to do now.

There's Nothing Pleasant About the Current Action

Timothy Collins
Mar 4, 2021 3:00 PM EST

The next good sized bounce in SPAC names, and maybe ARKK names, might be the last exit off the bagholder highway.

Nike's Charts and Indicators Are Still Bearish

Bruce Kamich
Mar 4, 2021 2:20 PM EST

Avoid the long side.

Listen to Mr. Market, Not Mr. Powell

Jim Collins
Mar 4, 2021 1:56 PM EST

Let's look at bonds, rates and, especially, inflation for a true picture of what's going on, and where to put your money.

Powell Supplies the Bears With Ammunition

James "Rev Shark" DePorre
Mar 4, 2021 1:20 PM EST

Picking good stocks is not going to help you much in this market right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login